Bizino MB, et al. - In patients with type 2 diabetes mellitus but not cardiovascular disease, researchers investigated liraglutide's effectiveness in improving diabetic cardiomyopathy. Participants were randomized to receive either liraglutide 1.8 mg/day (n=23) or placebo (n=26). They found that liraglutide caused attenuation of early left ventricular (LV) diastolic filling and LV filling pressure, thereby unloading the left ventricle. A reduction of LV systolic function was evident, and LV systolic function remained within normal range.